Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Safety signals remain to be a big challenge facing this patient population, explains Pegram. While TKIs are active, they are difficult to administer due to adverse events. Therefore, it is important to be mindful when treating these patients.

When treating with immunotherapies, off-target autoimmune events are concerning, states Pegram. More clinical trials are needed to discover the safest and most efficacious doses.